Satilmis BİLGİN
(Bolu Abant İzzet Baysal Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Bolu, Türkiye)
Gizem KAHVECİ
(Bolu Abant İzzet Baysal Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Bolu, Türkiye)
Burçin Meryem ATAK TEL
(Bolu Abant İzzet Baysal Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Bolu, Türkiye)
Özge KURTKULAĞI
(Bolu Abant İzzet Baysal Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Bolu, Türkiye)
Mehmet Ali KÖSEKLİ
(Bolu Abant İzzet Baysal Üniversitesi, Tıp Fakültesi, Gastroenteroloji Anabilim Dalı, Bolu, Türkiye)
Yıl: 2021Cilt: 4Sayı: 2ISSN: 2618-6454 / 2618-6454Sayfa Aralığı: 148 - 153İngilizce

60 0
Platelet to lymphocyte ratio in differentiation of benign and malignant thyroid nodules
Aim: Differentiation of thyroid nodules, either as benign or malignant, is a real diagnostic challenge.Inflammation has an important role in development of the malignancy. Therefore, inflammatory markers areassociated with malignant thyroid nodules. Platelet /lymphocyte ratio (PLR) is also one of the novelinflammatory indices derived from hemogram tests. We hypothesized whether PLR was associated withmalignant thyroid nodules. For this purpose, we compared PLR levels of the patients with benign thyroidnodules to the PLR of the subjects with malignant nodules.Methods: The subjects who visited outpatient internal medicine clinics of our institution with a diagnosis ofthyroid nodule were enrolled to the present retrospective study. According to the examination of the fine needleaspiration cytology (FNAC) specimen of the nodules, patients grouped into benign or malignant nodule groups.PLR of groups were compared.Results: Median PLR values of the benign and malignant thyroid nodule groups were 106 (48-432) % and 119(48-365) %, respectively (p=0.001). PLR value higher than 106% has 69% sensitivity and 51% specificity indetecting malignant nodules (AUC: 0.59, p=0.001, 95% CI: 0.54-0.65). PLR was positively correlated withTSH level (r=0.10, p=0.34).Conclusion: We suggest that elevated PLR could be an additional tool to differentiate malignant thyroidnodules from benign ones in supportive of sonography, scintigraphy and cytology.
DergiAraştırma MakalesiErişime Açık
  • [1]Tunbridge WM, Evered DC, Hall R et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol. 1977; 7 (6): 481-93.
  • [2]Guth S, Theune U, Aberle J et al. Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination. Eur J Clin Invest. 2009; 39 (8): 699-706.
  • [3]Allavena P, Sica A, Solinas G et al. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol. 2008; 66 (1): 1-9.
  • [4]Ozmen S, Timur O, Calik I et al. Neutrophillymphocyte ratio (NLR) and plateletlymphocyte ratio (PLR) may be superior to C-reactive protein (CRP) for predicting the occurrence of differentiated thyroid cancer. Endocr Reg. 2017; 51 (3): 131-36.
  • [5]Aktas G, Sit M, Karagoz I et al. Could Red Cell Distribution Width be a Marker of Thyroid Cancer? J Coll Physicians Surg Pak. 2017; 27 (9): 556-58.
  • [6]Sit M, Aktas G, Erkol H et al. Neutrophil to Lymphocyte Ratio is Useful in Differentiation of Malign and Benign Thyroid Nodules. P R Health Sci J. 2019; 38 (1): 60-63.
  • [7]Sit M, Aktas G, Ozer B et al. Mean Platelet Volume: an overlooked herald of malignant thyroid nodules. Acta Clin Croat. 2019; 58 (3): 417-20.
  • [8]Atak B, Aktas G, Duman TT et al. Diabetes control could through platelet-tolymphocyte ratio in hemograms. Rev Assoc Med Bras. 2019; 65 (1): 38-42.
  • [9]Kwon HC, Kim SH, Oh SY et al. Clinical significance of preoperative neutrophillymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers. 2012; 17 (3): 216-22.
  • [10]Wen H, Chen Y. The predictive value of platelet to lymphocyte ratio and D-dimer to fibrinogen ratio combined with WELLS score on lower extremity deep vein thrombosis in young patients with cerebral hemorrhage. Neurol Sci. 2021. doi: 10.1007/s10072-020-05007-y
  • [11]Eslamijouybari M, Heydari K, Maleki I et al. Neutrophil-to-Lymphocyte and Platelet-toLymphocyte Ratios in COVID-19 Patients and Control Group and Relationship with Disease Prognosis. Caspian J Intern Med. 2020; 11 (Suppl 1): 531-35.
  • [12]Nair PR, Maitra S, Ray BR et al. Neutrophilto-lymphocyte Ratio and Platelet-tolymphocyte Ratio as Predictors of the Early Requirement of Mechanical Ventilation in COVID-19 Patients. Ind J Crit Care Med. 2020; 24 (11): 1143-44.
  • [13]Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420 (6917): 860-67.
  • [14]Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140 (6): 883-99.
  • [15]Muzykiewicz KP, Iwanska E, Janeczek M et al. The analysis of the prognostic value of the neutrophil/ lymphocyte ratio and the platelet/lymphocyte ratio among advanced endometrial cancer patients. Ginekol Pol. 2021;92(1):16-23.
  • [16]Zhuang Z, Li Y, Hong Y et al. A novel prognostic Score based on systemic inflammatory Biomarkers for Patients with oral squamous Cell carcinoma. Oral Dis. 2021. doi: 10.1111/odi.13774.
  • [17]Wang P, Wang Z, Liu Y et al. Prognostic value of platelet-associated biomarkers in rectal cancer patients received neoadjuvant chemoradiation: A retrospective study. Cancer Radiother. 2021;S1278-3218(20): 30342-345.
  • [18]Liu K, Jiang G, Fang N et al. Platelet/lymphocyte ratio is a significant prognostic factor for targeted therapy in patients with EGFR-mutated non-small-cell lung cancer. J Int Med Res. 2020; 48 (12): 300060520980205.
  • [19]Wang N, Li C, Yang Y et al. The Usage of Platelet/Lymphocyte Ratio, Carbohydrate Antigen 125 Combined with Magnetic Resonance Diffusion Weighted Imaging in Diagnosis of Recurrent Ovarian Cancer and Neuropathic Pain. World Neurosurg. 2020;S1878-8750(20): 32502-X.
  • [20]Pan Q, Wang Y, Wang G. The Association Between Hyperhomocysteinemia and Thyroid Nodule Prevalence in an Adult Population. Metab Syndr Relat Disord. 2020;18(8):368-72.
  • [21]Moon WJ, Jung SL, Lee JH et al. Benign and malignant thyroid nodules: US differentiation--multicenter retrospective study. Radiology. 2008; 247 (3): 762-70.
  • [22]Kountakis SE, Skoulas IG, Maillard AA. The radiologic work-up in thyroid surgery: fine-needle biopsy versus scintigraphy and ultrasound. Ear Nose Throat J. 2002; 81 (3): 151-54.
  • [23]Maia FF, Zantut-Wittmann DE. Thyroid nodule management: clinical, ultrasound and cytopathological parameters for predicting malignancy. Clinics (Sao Paulo). 2012; 67 (8): 945-54.

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.